Zolinza Merck & Co., Inc. - Treatment for Cutaneous T-cell Lymphoma
Zolinza is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin’s lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.Posted: October 2006
